Assertio (US:ASRT) Globenewswire·2025-10-28 13:15Company Leadership Transition - Assertio Holdings, Inc. has appointed Mark L. Reisenauer as the new CEO, effective immediately, succeeding Brendan P. O'Grady [1][2] - The Board of Directors believes Reisenauer is well-suited to lead the company into its next growth phase, focusing on enhancing efficiency and delivering long-term value [2] Upcoming Financial Results - Assertio will release its third quarter 2025 financial results on November 10, 2025, after market close [3] - A live webcast conference call will be held at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide updates on the company's strategic plans for 2025 [3] Mark Reisenauer's Background - Mark Reisenauer has over 30 years of experience in the oncology space, previously serving as President of U.S. Commercial at Astellas Pharmaceuticals, where he grew sales to nearly $5 billion [5] - He has a strong track record in building and launching franchises and products, making him highly qualified for the CEO role at Assertio [2][5] Company Overview - Assertio is a pharmaceutical company focused on marketing differentiated products in oncology, neurology, and pain management [6][7]